A new study will examine whether nusinersen may help patients previously treated with Evrysdi since Evrysdi shows a reduced drug concentration as patients' weight and age increase, Biogen said. "Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug," published at 7:45 a.m. ET, incorrectly suggested that some patients in the new study might continue to be treated with Evrysdi in addition to nusinersen.

(END) Dow Jones Newswires

September 15, 2021 14:29 ET (18:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Biogen Charts.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Biogen Charts.